2020

04 March, 2020

New disinfection spray from Lipidor and Aurena Laboratories

In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have suffered from supply… Read more

25 February, 2020 R

Lipidor AB re-publishes year-end report for 2019

Yesterday, 24[ ]February at 4.59pm (CET), Lipidor AB (publ) published our year-end report for 2019 one day earlier than announced. We hereby re-publish the year-end report 2019 on the date and time… Read more

24 January, 2020 R

Lipidor announces positive topline results of AKP01 Phase III clinical study using calcipotriol spray against psoriasis

Lipidor AB (Nasdaq First North: LIPI) today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate… Read more

02 January, 2020

Lipidor AB (publ): The Knowledge Foundation funds collaborative project to study the effects of drug formulations on the skin barrier

Lipidor AB (Nasdaq First North: LIPI), in collaboration with Malmö University, MediGelium AB, Larodan AB and ERCO Pharma AB, has been awarded a research grant… Read more

17 December, 2019

Lipidor AB (publ) updates timetable for results from ongoing phase III study - marginal shift in results reporting

Lipidor AB (Nasdaq First North: LIPI) today announces that results from the ongoing phase-III study, of calcipotriol spray against mild to moderate psoriasis, will be… Read more

10 December, 2019 R

Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products

Lipidor AB (“Lipidor”), a Swedish topical drug development company, and Cannassure Therapeutics Ltd (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products,… Read more

21 November, 2019 R

Correction: Lipidor AB (publ) publishes interim report for Q3 2019

The correction relates to the non-attached interim report for Q3 in the press release and the incorrect link to the interim report for Q3 on… Read more

07 November, 2019 R

Lipidor Announces Last Patient Out in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has completed treatment in the phase III study evaluating the efficacy of using a sprayable calcipotriol… Read more

23 September, 2019 R

Lipidor has been approved for listing on the Nasdaq First North Growth Market with first day of trading on September 27, 2019

Nasdaq Stockholm AB today approved the application of Lipidor AB ("Lipidor" or "the Company") for admission to trading of Lipidor shares and TO1 series warrants… Read more

16 September, 2019 R

Lipidor’s New Share Issue Achieves 540 % Subscription

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing on the Nasdaq… Read more

09 September, 2019 R

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate… Read more

27 August, 2019 R

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market [updated]

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum of 2,100,000 units… Read more

26 August, 2019

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum of 2,100,000 units… Read more

20 June, 2019

Decisions from Annual General Meeting of Lipidor AB, 20 June 2019

(Stockholm 20 June, 2019) On 20 June2019, the Annual General Meeting (”AGM”) of Lipidor AB (publ) was held in Stockholm. Read below for a summary of… Read more

14 January, 2019

Lipidor AB successfully completes private placement of 20 MSEK

14 January 2019, Stockholm, Sweden. Lipidor AB, a Swedish drug development company with an ongoing fully financed Phase III study for a psoriasis medication, has… Read more

Load more
25 February, 2020 R

Lipidor AB re-publishes year-end report for 2019

Yesterday, 24[ ]February at 4.59pm (CET), Lipidor AB (publ) published our year-end report for 2019 one day earlier than announced. We hereby re-publish the year-end report 2019 on the date and time… Read more

24 January, 2020 R

Lipidor announces positive topline results of AKP01 Phase III clinical study using calcipotriol spray against psoriasis

Lipidor AB (Nasdaq First North: LIPI) today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate… Read more

10 December, 2019 R

Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products

Lipidor AB (“Lipidor”), a Swedish topical drug development company, and Cannassure Therapeutics Ltd (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products,… Read more

21 November, 2019 R

Correction: Lipidor AB (publ) publishes interim report for Q3 2019

The correction relates to the non-attached interim report for Q3 in the press release and the incorrect link to the interim report for Q3 on… Read more

07 November, 2019 R

Lipidor Announces Last Patient Out in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has completed treatment in the phase III study evaluating the efficacy of using a sprayable calcipotriol… Read more

23 September, 2019 R

Lipidor has been approved for listing on the Nasdaq First North Growth Market with first day of trading on September 27, 2019

Nasdaq Stockholm AB today approved the application of Lipidor AB ("Lipidor" or "the Company") for admission to trading of Lipidor shares and TO1 series warrants… Read more

16 September, 2019 R

Lipidor’s New Share Issue Achieves 540 % Subscription

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing on the Nasdaq… Read more

09 September, 2019 R

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate… Read more

27 August, 2019 R

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market [updated]

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum of 2,100,000 units… Read more

Load more